ReadoutIn window
Bristol-Myers Squibb — Deucravacitinib
Phase 3 primary completion: Efficacy and safety of Deucravacitinib in adults with active Sjögren's Syndrome.
- Date
- Nov 2026
- Type
- Readout
- Ticker
- BMY
- Indication
- Sjögren's Syndrome
ReadoutIn window
Phase 3 primary completion: Efficacy and safety of Deucravacitinib in adults with active Sjögren's Syndrome.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.